The company exports fast-moving consumer goods, cosmetics, and pharmaceutical products, primarily targeting markets in Africa and other international regions.
The company lacks a durable competitive advantage, as evidenced by negative net margins and an average ROCE of only 3.9%, which is well below the cost of capital. While they possess established brands, the lack of pricing power is confirmed by the inability to maintain profitability despite significant revenue scale.
Capital allocation has been poor, characterized by high debt levels (D/E of 2.6) and investments in associates that were later exited. The company has failed to generate positive average ROE or net margins over the period, suggesting reinvested capital is not earning a return.
The company's collapse was driven by a lethal combination of excessive leverage and a business model that incinerated capital. Despite growing revenue, the inability to generate positive net margins meant that every new sale required more debt to fund inventory and receivables. The high debt-to-equity ratio eventually led to a liquidity crunch when interest coverage could no longer sustain the borrowing costs. The total management reset and name change failed to fix the underlying lack of pricing power, and the significant provisions for doubtful debts eventually forced a massive write-down that wiped out shareholder equity.
RichFakir rates Krowniq Ltd's business quality as poor — 16/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Krowniq Ltd is trading about 25% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Krowniq Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Krowniq Ltd's fair value is about ₹38 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →